These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 23682110)

  • 1. Macitentan for the treatment of idiopathic pulmonary fibrosis: the randomised controlled MUSIC trial.
    Raghu G; Million-Rousseau R; Morganti A; Perchenet L; Behr J;
    Eur Respir J; 2013 Dec; 42(6):1622-32. PubMed ID: 23682110
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Macitentan, a tissue-targeting endothelin receptor antagonist for the potential oral treatment of pulmonary arterial hypertension and idiopathic pulmonary fibrosis.
    Raja SG
    Curr Opin Investig Drugs; 2010 Sep; 11(9):1066-73. PubMed ID: 20730702
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis.
    King TE; Brown KK; Raghu G; du Bois RM; Lynch DA; Martinez F; Valeyre D; Leconte I; Morganti A; Roux S; Behr J
    Am J Respir Crit Care Med; 2011 Jul; 184(1):92-9. PubMed ID: 21474646
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety, tolerability, pharmacokinetics, and pharmacodynamics of macitentan, an endothelin receptor antagonist, in an ascending multiple-dose study in healthy subjects.
    Sidharta PN; van Giersbergen PL; Dingemanse J
    J Clin Pharmacol; 2013 Nov; 53(11):1131-8. PubMed ID: 23900878
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis.
    King TE; Behr J; Brown KK; du Bois RM; Lancaster L; de Andrade JA; Stähler G; Leconte I; Roux S; Raghu G
    Am J Respir Crit Care Med; 2008 Jan; 177(1):75-81. PubMed ID: 17901413
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis.
    Richeldi L; Costabel U; Selman M; Kim DS; Hansell DM; Nicholson AG; Brown KK; Flaherty KR; Noble PW; Raghu G; Brun M; Gupta A; Juhel N; Klüglich M; du Bois RM
    N Engl J Med; 2011 Sep; 365(12):1079-87. PubMed ID: 21992121
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Macitentan for the treatment of pulmonary arterial hypertension.
    Hong IS; Coe HV; Catanzaro LM
    Ann Pharmacother; 2014 Apr; 48(4):538-47. PubMed ID: 24458948
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Macitentan for the treatment of portopulmonary hypertension (PORTICO): a multicentre, randomised, double-blind, placebo-controlled, phase 4 trial.
    Sitbon O; Bosch J; Cottreel E; Csonka D; de Groote P; Hoeper MM; Kim NH; Martin N; Savale L; Krowka M
    Lancet Respir Med; 2019 Jul; 7(7):594-604. PubMed ID: 31178422
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial.
    King TE; Albera C; Bradford WZ; Costabel U; Hormel P; Lancaster L; Noble PW; Sahn SA; Szwarcberg J; Thomeer M; Valeyre D; du Bois RM;
    Lancet; 2009 Jul; 374(9685):222-8. PubMed ID: 19570573
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Macitentan, a dual endothelin receptor antagonist for the treatment of pulmonary arterial hypertension, does not affect cardiac repolarization in healthy subjects.
    Lindegger N; Sidharta PN; Reseski K; Dingemanse J
    Pulm Pharmacol Ther; 2014 Oct; 29(1):41-8. PubMed ID: 24813561
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1): results from the multicentre, phase 2, randomised, double-blind, placebo-controlled study.
    Ghofrani HA; Simonneau G; D'Armini AM; Fedullo P; Howard LS; Jaïs X; Jenkins DP; Jing ZC; Madani MM; Martin N; Mayer E; Papadakis K; Richard D; Kim NH;
    Lancet Respir Med; 2017 Oct; 5(10):785-794. PubMed ID: 28919201
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Macitentan and morbidity and mortality in pulmonary arterial hypertension.
    Pulido T; Adzerikho I; Channick RN; Delcroix M; Galiè N; Ghofrani HA; Jansa P; Jing ZC; Le Brun FO; Mehta S; Mittelholzer CM; Perchenet L; Sastry BK; Sitbon O; Souza R; Torbicki A; Zeng X; Rubin LJ; Simonneau G;
    N Engl J Med; 2013 Aug; 369(9):809-18. PubMed ID: 23984728
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Imatinib treatment for idiopathic pulmonary fibrosis: Randomized placebo-controlled trial results.
    Daniels CE; Lasky JA; Limper AH; Mieras K; Gabor E; Schroeder DR;
    Am J Respir Crit Care Med; 2010 Mar; 181(6):604-10. PubMed ID: 20007927
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Macitentan on the Development of New Ischemic Digital Ulcers in Patients With Systemic Sclerosis: DUAL-1 and DUAL-2 Randomized Clinical Trials.
    Khanna D; Denton CP; Merkel PA; Krieg T; Le Brun FO; Marr A; Papadakis K; Pope J; Matucci-Cerinic M; Furst DE; ;
    JAMA; 2016 May; 315(18):1975-88. PubMed ID: 27163986
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of once-daily fluticasone furoate/vilanterol on 24-hour pulmonary function in patients with chronic obstructive pulmonary disease: a randomized, three-way, incomplete block, crossover study.
    Boscia JA; Pudi KK; Zvarich MT; Sanford L; Siederer SK; Crim C
    Clin Ther; 2012 Aug; 34(8):1655-66.e5. PubMed ID: 22789766
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early Experience of Macitentan for Pulmonary Arterial Hypertension in Adult Congenital Heart Disease.
    Herbert S; Gin-Sing W; Howard L; Tulloh RMR
    Heart Lung Circ; 2017 Oct; 26(10):1113-1116. PubMed ID: 28237536
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial of BMS-986020, a Lysophosphatidic Acid Receptor Antagonist for the Treatment of Idiopathic Pulmonary Fibrosis.
    Palmer SM; Snyder L; Todd JL; Soule B; Christian R; Anstrom K; Luo Y; Gagnon R; Rosen G
    Chest; 2018 Nov; 154(5):1061-1069. PubMed ID: 30201408
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of macitentan on hospitalizations: results from the SERAPHIN trial.
    Channick RN; Delcroix M; Ghofrani HA; Hunsche E; Jansa P; Le Brun FO; Mehta S; Pulido T; Rubin LJ; Sastry BKS; Simonneau G; Sitbon O; Souza R; Torbicki A; Galiè N
    JACC Heart Fail; 2015 Jan; 3(1):1-8. PubMed ID: 25457902
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CC-chemokine ligand 2 inhibition in idiopathic pulmonary fibrosis: a phase 2 trial of carlumab.
    Raghu G; Martinez FJ; Brown KK; Costabel U; Cottin V; Wells AU; Lancaster L; Gibson KF; Haddad T; Agarwal P; Mack M; Dasgupta B; Nnane IP; Flavin SK; Barnathan ES
    Eur Respir J; 2015 Dec; 46(6):1740-50. PubMed ID: 26493793
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Twice daily N-acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double-blind placebo-controlled trial.
    Zheng JP; Wen FQ; Bai CX; Wan HY; Kang J; Chen P; Yao WZ; Ma LJ; Li X; Raiteri L; Sardina M; Gao Y; Wang BS; Zhong NS;
    Lancet Respir Med; 2014 Mar; 2(3):187-94. PubMed ID: 24621680
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.